Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)

Year 2022, Volume: 2 Issue: 2, 59 - 65, 25.12.2022

Gül Ateş , Melise Gözde Kütük , Şebnem Bıçakcı

Abstract

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a small vessel disease. It is an autosomal dominant inherited disease caused by a mutation in the Notch3 gene. It affects many systems as it gives multiple symptoms. The earliest and most common symptom is migraine. It is thought that the Notch3 gene may act as a sensitivity marker in migraine with aura. It has been reported more frequently with ischemic stroke attack. It may also present with acute leukoencephalopathy, accompanied by seizures and cognitive changes. Psychiatric symptoms, defined as vascular depression and complicating the patient's social life, are observed. In addition, due to small vessel disease, we may encounter peripheral neuropathy and myopathy in some patients. Family screening and genetic counseling have an important place here, as it can show different phenotypes due to environmental effects and is an autosomal dominant disease. In this article, we tried to compile and present the effects, symptoms and neuropathology of CADASIL disease.

Keywords

CADASIL, Notch3 gene, mutation

Serebral otozomal dominant arteriyopati ile subkortikal enfarktlar ve lökoensefalopati (CADASIL)

Abstract

Serebral otozomal dominant arteriyopati ile subkortikal enfarklar ve lökoensefalopati (CADASIL) küçük damar hastalığıdır. Notch3 genindeki mutasyon sonucunda ortaya çıkan otozomal dominant geçişli bir hastalıktır. Birden fazla semptom verdiğinden bir sürü sistemi etkiler. En erken ve sık belirtisi migrendir. Auralı migrende Notch3 geninin duyarlılık belirteci olarak davranabileceği düşünülmektedir. Daha sık iskemik inme atağıyla raporlanmıştır. Nöbetler ve bilişsel değişikliklerle beraber seyreden akut lökoensefalopati tablosuyla da gelebilir. Vasküler depresyon olarak tanımlanan ve hastanın sosyal hayatını zorlaştıran psikiyatrik semptomlar görülmektedir. Bunun yanı sıra küçük damar hastalığı olduğundan bazı hastalarda periferik nöropati ve myopatiye de rastlayabiliriz. Çevre etkisiyle de değişik fenotip gösterebildiği ve otozomal dominant bir hastalık olması sebebiyle aile taraması ve genetik danışmanlık burada önemli bir yer tutmaktadır. Bu makalede CADASIL hastalığının etkileri, semptomları ve nöropatolojisi gözden geçirilmiştir.

Keywords

CADASIL, , Notch3 geni, mutasyon

References

• 1. Joutel A, Corpechot C, Ducros A, Vahedi K, Chabriat H, Mouton P, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia.Nature. 1996;383:707-10.
• 2. Narayan SK, Gorman G, Kalaria RN, Ford GA, Chinnery PF. The minimum prevalence of cadasil in England. Neurology. 2012;78:1025-7.
• 3. Boussier Mg, Tournier- Lasserve E. Summary of the proceedings of the first International Workshop on CADASIL. Stroke. 1994;25:704-7.
• 4. Sabbadini G, Francia A, Calandriello L, Di Biasi C, Trasimeni G, Gualdi GF et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL). Clinical, neuroimaging, pathological and genetic study of a large Italian family. Brain. 1995;118:207-15.
• 5. Mas JL, Dilouya A, de Recando J. A familial disorder with subcortical ischemic strokes, dementia and leukoencephalopathy. Neurology. 1992;42:1015-9.
• 6. Donnini I, Nannucci S, Valenti R, Pescini F, Bianchi S, Inzitari D et al. Acetazolamide for the prophylaxis of migraine in CADASIL: a preliminary experience. J Headache Pain. 2012;13:299-302.
• 7. Monteiro C, Barros J, Tipa R, Pereira-Monteiro J. Sporadic hemiplegic migraine as the initial manifestation of Cadasil. Cephalalgia. 2012;32:255-7.
• 8. Benisty S, Reyes S, Godin O, Herve D, Zieren N, Jouvent E et al. White matter lesions without lacuner infarcts in CADASIL. J Alzheimers Dis. 2012;29:903-11.
• 9. Dominquez-Sanchez FJ, Lasa-Aristu A, Gomi-Imızcoz M. Intelligence impairment, personality and psychopathology disturbances in a familiy affected with CADASIL. Span J Psychol. 2011;14:936-43.
• 10. Uchino M. The pathomechanism and treatment of CADASIL. Rinsho Shinkeigaku. 2011;51:945-8.
• 11. Joutel A, Corpechot C, Ducros A, Vahedi K, Chabriat H, Mouton P et al. Notch3 mutations in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a mendelian condition causing stroke and vascular dementia. Ann N Y Acad Sci. 1997;826:213-7.
• 12. Yuan P, Salvadore G, Li X, Zhang L, Du J, Chen G et al. Valproate activates the Notch3/c-FLIP signaling cascade: a strategy to attenuate white matter hyperintensities in bipolar disorder in late life? Bipolar Disord. 2009;11:256-69.
• 13. Eikermann-Haerter K, Yuzawa I, Dilekoz E, Joutel A, Moskowitz MA, Ayata C. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy syndrome mutations increase susceptibility to spreading depression. Ann Neurol. 2011;69:413–8.
• 14. Liem MK, Oberstein SA, van der Grond J, Ferrari MD, Haan J. CADASIL and migraine: a narrative review. Cephalalgia. 2010;30:1284–9.
• 15. Dichgans M, Mayer M, Uttner I, Brűning R, Műller-Hőcker J, Rungger G et al. The phenotypic spectrum of CADASIL: clinical findings in 102 cases. Ann Neurol. 1998;44:731–9.
• 16. Opherk C, Peters N, Herzog J, Luedtke R, Dichgans M. Long-term prognosis and causes of death in CADASIL: a retrospective study in 411 patients. Brain. 2004;127:2533–9.
• 17. Choi JC, Lee KH, Song SK, Lee JS, Kang SY, Kang JH. Screening for NOTCH3 gene mutations among 151 consecutive Korean patients with acute ischemic stroke. J Stroke Cerebrovasc Dis. 2013;22:608–14.
• 18. Yin X, Wu D, Wan J, Yan S, Lou M, Zhao G et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: Phenotypic and mutational spectrum in patients from mainland China. Int J Neurosci. 2015;125:585–92.
• 19. Kang HG, Kim JS. Intracranial arterial disease in CADASIL patients. J Neurol Sci. 2015;359:347–50.
• 20. 20.Rutten JW, Haan J, Terwindt GM, van Duinen SG, Boon EM, Lesnik Oberstein SA. Interpretation of NOTCH3 mutations in the diagnosis of CADASIL. Expert Rev Mol Diagn. 2014;14:593–603.
• 21. Schon F, Martin RJ, Prevett M, Clough C, Enevoldson TP, Markus HS. “CADASIL coma”: an underdiagnosed acute encephalopathy. J Neurol Neurosurg Psychiatry. 2003;74:249–52.
• 22. Peters N, Opherk C, Danek A, Ballard C, Herzog J, Dichgans M. The pattern of cognitive performance in CADASIL: a monogenic condition leading to subcortical ischemic vascular dementia. Am J Psychiatry. 2005;162:2078–85.
• 23. Charlton RA, Morris RG, Nitkunan A, Markus HS. The cognitive profiles of CADASIL and sporadic small vessel disease. Neurology. 2006;66:1523–6.
• 24. De Guio F, Reyes S, Vignaud A, Duering M, Ropele S, Duchesnay E, et al. In vivo high-resolution 7 Tesla MRI shows early and diffuse cortical alterations in CADASIL. PLoS One. 2014;9:e106311.
• 25. Jouvent E, Reyes S, De Guio F, Chabriat H. Reaction time is a marker of early cognitive and behavioural alterations in pure cerebral small vessel disease. J Alzheimer Dis. 2015;47:413–9.
• 26. Reyes S, Viswanathan A, Godin O, Dufouil C, Benisty S, Hernandez K, et al. Apathy: a major symptom in CADASIL. Neurology. 2009;72:905–10.
• 27. Brookes RL, Hollocks MJ, Tan RY, Morris RG, Markus HS. Brief screening of vascular cognitive impairment in patients with cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy without dementia. Stroke. 2016;47:2482–7.
• 28. Jouvent E, Duchesnay E, Hadj-Selem F, De Guio F, Mangin JF, Hervé D et al. Prediction of 3-year clinical course in CADASIL. Neurology. 2016;87:1787–95.
• 29. Romàn GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC. Subcortical ischaemic vascular dementia. Lancet Neurol. 2002;1:426–36.
• 30. Righart R, Duering M, Gonik M, Jouvent E, Reyes S, Hervé D et al. Impact of regional cortical and subcortical changes on processing speed in cerebral small vessel disease. Neuroimage Clin. 2013;2:854–61.
• 31. Jouvent E, Poupon C, Gray F, Paquet C, Mangin JF, Le Bihan D et al. Intracortical infarcts in small vessel disease: a combined 7-T postmortem MRI and neuropathological case study in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Stroke. 2011;42:e27–30.
• 32. Duering M, Righart R, Csanadi E, Jouvent E, Hervè D, Chabriat H et al. Incident subcortical infarcts induce focal thinning in connected cortical regions. Neurology. 2012;79:2025–8.
• 33. Taillia H, Chabriat H, Kurtz A, Verin M, Levy C, Vahedi K et al. Cognitive alterations in non-demented CADASIL patients. Cerebrovasc Dis. 1998;8:97–101.
• 34. Amberla K, Wäljas M, Tuominen S, Almkvist O, Pőyhőnen M, Tuisku S et al. Insidious cognitive decline in CADASIL. Stroke. 2004;35:1598–602.
• 35. Singhal S, Bevan S, Barrick T, Rich P, Markus HS. The influence of genetic and cardiovascular risk factors on the CADASIL phenotype. Brain. 2004;127:2031–8.
• 36. Ciolli L, Pescini F, Salvadori E, Del Bene A, Pracucci G, Poggesi A et al. Influence of vascular risk factors and neuropsychological profile on functional performances in CADASIL: results from the MIcrovascular LEukoencephalopathy Study (MILES) Eur J Neurol. 2014;21:65–71.
• 37. Opherk C, Peters N, Holtmannspötter M, Gschwendtner A, Müller-Myhsok B, Dichgans M. Heritability of MRI lesions volume in CADASIL: evidence for genetic modifiers. Stroke. 2006;37:2684–9.
• 38. Opherk C, Gonik M, Duering M, Malik R, Jouvent E, Hervé D et al. Genome-wide genotyping demonstrates a polygenic risk score associated with white matter hyperintensity volume in CADASIL. Stroke. 2014;45:968–72.
• 39. Gesierich B, Opherk C, Rosand J, Gonik M, Malik R, Jouvent E et al. APOE ɛ2 is associated with white matter hyperintensity volume in CADASIL. J Cereb Blood Flow Met. 2016;36:199–203a.
• 40. Gunda B, Hervé D, Godin O, Bruno M, Reyes S, Alili N et al. Effects of gender on the phenotype of CADASIL. Stroke. 2012;4:137–41.
• 41. Escary JL, Cécillon M, Maciazek J, Lathrop M, Tournier-Lasserve E, Joutel A. Evaluation of DHPLC analysis in mutational scanning of Notch3, a gene with high G-C content. Hum Mutat. 2000;16:518–26.
• 42. Joutel A, Vahedi K, Corpechot C, Troesch A, Chabriat H, Vayssière C et al. Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients. Lancet. 1997;350:1511–5.
• 43. Rutten JW, Haan J, Terwindt GM, van Duinen SG, Boon EM, Lesnik Oberstein SA. Interpretation of NOTCH3 mutations in the diagnosis of CADASIL. Expert Rev Mol Diagn. 2014;14:593–603.
• 44. Bianchi S, Dotti MT, Gallus GN, D’Eramo C, Di Donato I, Bernardi L et al. First deep intronic mutation in the NOTCH3 gene in a family with late-onset CADASIL. Neurobiol Aging. 2013;34:2234.e9-12.
• 45. Finsterer J. Neuromuscular implications in CADASIL. Cerebrovasc Dis. 2007;24:401–4.
• 46. Abou Al-Shaar H, Qadi N, Al-Hamed MH, Meyer BF, Bohlega S. Phenotypic comparison of individuals with homozygous or heterozygous mutation of NOTCH3 in a large CADASIL family. J Neurol Sci. 2016;367:239–43.
• 47. Markus HS, Martin RJ, Simpson MA, Dong YB, Ali N, Crosby AH et al. Diagnostic strategies in CADASIL. Neurology. 2002;59:1134–8.
• 48. Malandrini A, Gaudiano C, Gambelli S, Berti G, Serni G, Bianchi S et al. Diagnostic value of ultrastructural skin biopsy studies in CADASIL. Neurology. 2007;68:1430–2.
• 49. Morroni M, Marzioni D, Ragno M, Di Bella P, Cartechini E, Pianese L et al. Role of electron microscopy in the diagnosis of CADASIL syndrome: a study of 32 patients. PLoS One. 2013;8:e65482.
• 50. Ishiko A, Shimizu A, Nagata E, Takahashi K, Tabira T, Suzuki N. Notch3 ectodomain is a major component of granular osmiophilic material (GOM) in CADASIL. Acta Neuropathol. 2006;112:333–9.
• 51. Tikka S, Mykkänen K, Ruchoux MM, Bergholm R, Junna M, Pöyhönen M et al. Congruence between NOTCH3 mutations and GOM in 131 CADASIL patients. Brain. 2009;132:933–9.
• 52. Arboleda-Velasquez JF, Manent J, Lee JH, Tikka S, Ospina C, Vanderburg CR et al. Hypomorphic Notch 3 alleles link Notch signaling to ischemic cerebral small-vessel disease. Proc Natl Acad Sci U S A. 2011;108:E128–35.
• 53. Joutel A, Favrole P, Labauge P, Chabriat H, Lescoat C, Andreux F et al. Skin biopsy immunostaining with a Notch3 monoclonal antibody for CADASIL diagnosis. Lancet. 2001;358:2049–51.
• 54. Auer DP, Pütz B, Gössl C, Elbel G, Gasser T, Dichgans M. Differential lesion patterns in CADASIL and sporadic subcortical arteriosclerotic encephalopathy: MR imaging study with statistical parametrical group comparison. Radiology. 2001;218:443–51.
• 55. Viswanathan A, Godin O, Jouvent E, O’Sullivan M, Gschwendtner A, Peters N et al. Impact of MRI markers in subcortical vascular dementia: a multi-modal analysis in CADASIL. Neurobiol Aging. 2010;31:1629–36.
• 56. Duering M, Zieren N, Hervé D, Jouvent E, Reyes S, Peters N et al. Strategic role of frontal white matter tracts in vascular cognitive impairment: a voxel-based lesion-symptom mapping study in CADASIL. Brain. 2011;134:2366–75.
• 57. Rutten JW, Dauwerse HG, Peters DJ, Goldfarb A, Venselaar H, Haffner C, et al. Therapeutic NOTCH3 cysteine correction in CADASIL using exon skipping: in vitro proof of concept. Brain. 2016;139:1123–35.
• 58. Dichgans M, Holtmannspötter M, Herzog J, Peters N, Bergmann M, Yousry TA. Cerebral microbleeds in CADASIL: a gradient-echo magnetic resonance imaging and autopsy study. Stroke. 2002;33:67–71.
• 59. Shobha N, Fang J, Hill MD. Do lacunar strokes benefit from thrombolysis? Evidence from the Registry of the Canadian Stroke Network. Int J Stroke. 2013;8:45–9.
• 60. Lesnik Oberstein SA, Jukema JW, Van Duinen SG, Macfarlane PW, van Houwelingen HC, Breuning MH et al. Myocardial infarction in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) Medicine (Baltimore). 2003;82:251–6.
• 61. Cumurciuc R, Henry P, Gobron C, Vicaut E, Bousser MG, Chabriat H et al. Electrocardiogram in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy patients without any clinical evidence of coronary artery disease: a case-control study. Stroke. 2006;37:1100–2.
• 62. Rufa A, Guideri F, Acampa M, Cevenini G, Bianchi S, De Stefano N et al. Cardiac autonomic nervous system and risk of arrhythmias in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) Stroke. 2007;38:276–80.
• 63. Piccirillo G, Magrì D, Mitra M, Rufa A, Zicari E, Stromillo ML et al. Increased QT variability in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Eur J Neurol. 2008;15:1216–21.
• 64. Zicari E, Tassi R, Stromillo ML, Pellegrini M, Bianchi S, Cevenini G et al. Right-to-left shunt in CADASIL patients: prevalence and correlation with clinical and MRI findings. Stroke. 2008;39:2155–7.
• 65. Mazzucco S, Anzola GP, Ferrarini M, Taioli F, Olivato S, Burlina AP et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy and right-to-left shunt: lack of evidence for an association in a prevalence study. Eur Neurol. 2008;61:46–9.
• 66. Mazzucco S, Anzola GP, Ferrarini M, Taioli F, Olivato S, Burlina AP et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy and right-to-left shunt: lack of evidence for an association in a prevalence study. Eur Neurol. 2008;61:46–9.
• 67. Goldman JS. Genetic testing and counseling in the diagnosis and management of young-onset dementias. Psychiatr Clin North Am. 2015;38:295–308.